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Abstract
Chronic lymphocytic leukemia (CLL) has been considered as an accumulative disease
deriving from defects in apoptosis, but recent studies showed that CLL is a dynamic
process in which monoclonal B cells proliferate within pseudofollicular proliferation
centers. Microenvironmental interactions are essential for the survival and prolifera‐
tion of CLL cells. The cell traffic between blood and secondary lymphoid tissues is
controlled by tissue-specific chemokines and their specific receptors on B lympho‐
cytes. Interstitial cell migration and adhesion events, predisposed by activational
stimuli, determine CLL cell localization. Stimulation through the B cell receptor plays
an important role in the expansion of the malignant clone in CLL. B cell receptors
become activated either in an antigen-dependent or in an antigen-independent
fashion in the secondary lymphatic tissues. However, low expression of the BCR
correlates with reduced induction of protein tyrosine kinase activity and defective
intracellular calcium mobilization and tyrosine phosphorylation. In contrast to
normal B cells, leukemic cells are poor antigen presenting cells. This is due to the fact
that leukemic cells have a reduced expression of costimulatory molecules and defects
in the formation of immunological synapse with T cells. Increased surface expression
of the costimulatory molecules on CLL cells correlates with their proliferation. At
present, conventional treatments are not directed to interactions between CLL cells
and their microenvironment, which is probably one of the reasons why, despite the
significant progress in treatment, the disease still remains incurable. In this regard,
identifying key biomarkers of intercellular interactions of neoplastic CLL population
in comparison with clinical laboratory abnormalities in CLL enable clarification of
essential processes in the development of the disease, and can be the basis for
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
stratifying patient groups in order to optimize therapeutic approaches, which will
make them relevant and promising.
Keywords: Chronic lymphocytic leukemia, Microenvironment, B cell receptor com‐
plex, Chemokine receptors, Cell adhesion molecules, Costimulatory receptors
1. Introduction
Chronic lymphocytic leukemia (CLL) is a disease with highly variable clinical manifestation
and course ranging from an aggressive, life-threatening disease to an indolent form, which
does not require treatment for many years. Current clinical staging systems are accessible and
easy to apply; however, they do not allow a sufficiently accurate opportunity for individual
assessment of the disease progression. Recently, significant progress has been made in our
understanding of CLL pathogenesis. CLL has been considered as an accumulative disease
deriving from an inherent defect in apoptosis, but recent studies showed that it is a dynamic
process, wherein monoclonal B cells proliferate within pseudofollicular proliferation centers,
hallmark of histopathology on this disease.
CLL cells interact with different types of cells, such as mesenchymal stromal cells (MSC),
monocyte-derived nurse-like cells (NLC), follicular dendritic cells (FDC), and T cells. Micro‐
environmental interactions are critical for the survival and proliferation of the leukemic cells.
A key role in the pathogenesis of the disease is given to the B cell receptors (BCRs), which in
the secondary lymphatic tissues become activated either by antigen-dependent or in an
antigen-independent fashion. The proliferative drive for the malignant cells is dependent from
external microenvironmental signals, and the CLL cells undergo apoptosis unless their
survival is reinforced by these external stimuli.
The cell traffic between the blood and secondary lymphoid tissues is controlled by tissue-
specific chemokines and their specific receptors. B cells express CD184 (CXCR4) as a functional
receptor, responsible for directing them mainly to the bone marrow (BM) environment. The
specific ligand CXCL12 has been shown to have anti-apoptotic effects on CLL cells and protect
them from spontaneous and chemotherapy-induced apoptosis in a contact-dependent manner
via stromal cells or nurse-like cells. The chemokine receptor CD185 (CXCR5) plays an impor‐
tant role in lymphocyte homing guiding B cells into the B cell zone of secondary lymphoid
organs and, together with CD197 (CCR7) (positioning in T cell zones of secondary lymphoid
tissues), ensures the close contact between T and B cells and activation. CLL cells secrete
chemokines as CCL3, CCL4, and CCL22, and therefore an autocrine way of stimulation on
monoclonal B cells is also suggested.
Interstitial cell migration and adhesion events, influenced by activating stimuli, determine CLL
cell localization. CD44 has been implicated in cell activation, migration, and tissue retention
via binding to its extracellular matrix ligand hyaluronan. CD38, CD49d, MMP9, and CD44 are
physically associated in a supramolecular cell surface complex; however, the complex is not
Leukemias - Updates and New Insights248
present in normal B cells. Taking into account the known properties of the individual molecules
and their functional overlap, it seems that the complex CD38 / CD49d / MMP9 / CD44 plays a
role in the migration into the tissues and in pro-survival signaling.
Stimulation through the BCR plays an important role in the selection and expansion of the
malignant clone in CLL, and the prognostic impact of the mutational status of immunoglobulin
heavy chain variable region (IGHV) genes could be considered as a consequence of the
relevance of this process in CLL. Low expression of the BCR correlates with the reduced
induction of protein tyrosine kinase activity and defective intracellular calcium mobilization
and tyrosine phosphorylation. Although there are individual differences among patients,
almost all CLL cases display very low levels of surface IgM and CD79b.
Costimulatory receptors on monoclonal B cells are expressed throughout B-cell development
and are implicated in cell survival and differentiation. CD40/CD40L interaction stimulates B
cells to proliferate, differentiate, upregulate costimulatory molecules, and increase antigen
presentation. In contrast to normal B cells, leukemic cells are poor antigen presenting cells.
This is due to the fact that leukemic cells have a reduced expression of costimulatory molecules
such as CD80 and CD86 and they have a defect in the formation of immunological synapse
with T cells. Surface expression of the costimulatory molecules CD80 and CD86 on CLL cells
is increased with their proliferation. CD267 (transmembrane activator calcium modulator and
cyclophilin ligand interactor - TACI) was identified as a receptor for B cell-activating factor
(BAFF) and A proliferation-inducing ligand (APRIL), two members of the TNF ligand family.
Both ligands induce proliferation, activation, and the survival of B cells, therefore the variable
expression of CD267, detected in patients with CLL, is probably important for the disease
characteristics.
The advances in fundamental understanding of the disease mechanisms in CLL will lead to
improved therapies for patients. At present, conventional treatments are not directed to the
interactions between CLL cells and their microenvironment, which is probably one of the
reasons why, despite the significant progress in treatment, the disease still remains incurable.
In this regard, studies on key biomarkers of intercellular interactions of the leukemic popula‐
tion enable clarification of key processes in the development of the disease, and can be the
basis for defining a separate risk patient group to optimize therapeutic approaches, which will
make them relevant and promising.
2. Microenvironment: Cells and interactions
Malignant B lymphocytes develop in the specific tissue microenvironment of the lymph node
and eventually in the bone marrow (BM), where they interact with various cell populations -
mesenchymal stromal cells (MSC), monocyte-derived nurse-like cells (NLC), follicular
dendritic cells (FDC), and T cells. Unlike the non-dividing cells circulating in the peripheral
blood (PB), tissue B cells proliferate (0.1–1% of the clone per day) [1]. This process occurs in
pseudofollicular proliferation centers [2, 3]. The interaction of the leukemic cells with the
microenvironment is similar to the model of normal B-cell engagement. Secondary lymphoid
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tissues are the place, where the B cell receptor (BCR) of monoclonal cells is activated [4] by
microbial antigens, autoantigens [5], or independently of antigens [6, 7]. Activation triggers a
signaling cascade facilitated by additional stimulatory signals, which results in the clone
growth.
2.1. Т lymphocytes
The interaction between monoclonal B lymphocytes and T lymphocytes is an important
component of the malignant process. T cells are extremely important for malignant prolifera‐
tion [8]. This was proven in a mouse xenograft model of CLL, in which activated CD41+ T cells
proved to be a necessary condition for CLL cell proliferation. In patients suffering from this
disease, T cells, mainly CD41+, often constitute a significant fraction of the lymphoid infiltrate
in bone marrow and lymph nodes [9], located within and around proliferation centers [10,
11]. One of the factors mediating the migration to the particular location is the expression of
the CD197 (CCR7) chemokine receptor on T cells, which facilitates recirculation through
secondary lymphoid tissues, following the gradient of its specific ligands CCL19 and CCL21
secreted in the T-cell zone of the lymph node [12]. The CD40 receptor, a key modulator of the
interaction between B- and T-lymphocytes, is stimulated by CD41+ T cells, which express its
ligand CD154 (CD40L) [13] and are co-localized with leukemic cells in the proliferation centers
[14]. In addition to the interactions through a direct intercellular contact, T lymphocytes secrete
soluble active molecules, interleukins, cytokines, and chemokines, which stimulate prolifera‐
tion and inhibit apoptosis of monoclonal B cells. Interleukin-4 (IL-4) inhibits spontaneous and
drug-induced apoptosis through a mechanism causing hyperproduction of Bcl-2 [15]. The
concurrent action of IL-2 [16] and Tumor Necrosis Factor-α (TNF-α) [17, 18] induces malignant
proliferation. Interferon-γ (IFNγ) [19], IFNα [20], and IL-13 [21] have a similar effect. Leukemic
cells also change the cellular component of the immune system by the production of immu‐
nosuppressive cytokines Tumor Growth Factor-β (TGF-β) [22] and IL-10 [23] and the expres‐
sion of low levels of the adhesion and costimulatory molecules [24], thus leading to the increase
and dysfunction of regulatory T lymphocytes [25, 26]. The gene expression profile (GEP) of T
cells from patients with CLL shows multiple changes in the genes participating mostly in
cellular differentiation, cytoskeleton, traffic, and cytotoxicity, which leads to an inhibited
immune response [27].
2.2. Mesenchymal Stromal Cells (MSCs)
МSCs are another major cellular component of tissue microenvironment. These cells are a
heterogeneous population, performing structural and functional interactions in normal
hemopoiesis [28]. Stromal cells secrete cytokines, chemokines, proangiogenic factors, and
extracellular matrix components. They express surface receptors, which mainly regulate
migration and facilitate the survival of CLL lymphocytes. The interaction of the leukemic cells
with МSC is in both directions. Not only monoclonal B cells migrate and are activated under
the influence of МSC, but vice versa, they also activate them and induce stromal-cell prolifer‐
ation and the secretion of mediators that increase the intensity of the malignant process [29,
30, 31, 32]. In the lymphoid tissues of patients with CLL, stromal cells are diffusely distributed
within the entire tissue and in the perivascular spaces, where they are mixed with leukemic
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cells [33]. CLL lymphocytes cultured with bone-marrow stromal cells avoid both the sponta‐
neous and drug-induced apoptosis [34, 35], through a mechanism dependent on direct
intercellular contact [34]. CXCL12 secreted by the stromal cells directs the migration of the
leukemic cells, which express the CXCR4 (CD184) receptor, through the stroma, and facilitate
the penetration beneath it (a phenomenon called pseudoemperipolesis) [35]. Surface receptors
and extracellular matrix elements induce anti-apoptotic stimuli in CLL lymphocytes, which
are in contact with the stroma. Adhesion of tumor cells to stromal cells is mediated by the β1
and β2 integrins [36]. MSCs express Vascular Cell Adhesion Molecule 1 (VCAM-1) [37].
Attachment of α4β1 integrin (CD49d/CD29) to VCAM-1 or to the extracellular matrix compo‐
nent fibronectin protects CLL cells from a spontaneous or Fludarabine-induced apoptosis [36,
38] by means of PI3K/AKT signals and the increase of BCL-XL [39]. The interaction of the
leukemic cell with the stroma also includes Matrix metalloproteinase-9 (MMP-9), Vascular
Endothelial Growth Factor (VEGF), and endothelial cells. MMP-9 is the main matrix metallo‐
proteinase produced by monoclonal B cells; it enhances extravasation and infiltration in
lymphoid tissue by means of the proteolytic degradation of basal membranes and extracellular
matrix components [40]. Regardless of its proteolytic activity, MMP-9 partially mediates anti-
apoptotic signals in the leukemic clone when cultured with bone-marrow stromal cells [41].
The attachment of MMP-9 to α4β1 and CD44v in CLL lymphocytes leads to the activation of
the Lck/Yes novel tyrosine kinase (LYN) and the Signal Transducer and Activator of Tran‐
scription 3 (STAT3) [39]. The expression of MMP-9 from leukemic cells is regulated by the
α4β1 integrins and CXCL12 [40]. Monoclonal B lymphocytes in the bone marrow and lymph
nodes express elevated levels of surface MMP-9, which shows the activation of tumor cells in
tissues microenvironment [39].
2.3. Follicular dendritic cells
Follicular dendritic cells (FDC) are accessory cells in normal germinal centers, where they catch
and retain antigen–antibody complexes on their cellular surfaces and present antigens to the
B cells. After binding to immune complexes, normal B lymphocytes in the germinal center
differentiate to memory B lymphocytes or plasma cells [42]. Normally, FDC are localized in
secondary lymphoid tissues but not in the bone marrow [43], while in CLL these cells are
localized in lymph node pseudofollicles [44, 45] and in nodular bone marrow infiltrates [46].
They secrete important anti-apoptotic and growth factors including BAFF, IL-15, and express
adhesion molecules Vascular Cell Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion
Molecule-1 (ICAM-1), Plexin B1, and CD44 [42, 44]. The effects of FDC on malignant B
lymphocytes have been studied on a follicular dendritic cell line (HK). There is evidence that
HK cells facilitate the survival of B cells, protect them from a spontaneous or drug-induced
apoptosis via the direct intercellular contact mechanism [47].
2.4. Tissue associated macrophages
Tissue associated macrophages have been studied in an in vitro model - NLC. In case of
continuous culturing of peripheral blood mononuclear cells of CLL patients, large, rounded,
rarely binuclear, CD68 expressing cells grow [48, 49]. NLC take this name since they contribute
to the growth and survival of the CLL cells. Cells of a similar phenotype can be found in vivo
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[49] in the secondary lymphoid organs of patients with CLL, but their number in the tissues
is generally low [33]. NLC differentiate from monocytes as this differentiation depends on
intercellular contacts with CLL lymphocytes. When monocytes from healthy individuals are
co-cultured with leukemic cells, they differentiate to NLC; however normal B cells are unable
to induce this differentiation [49]. NLC secrete chemokines (CXCL12 and CXCL13) and growth
factors such as BAFF and APRIL, hold leukemic cells within tissues, and facilitate their survival
and proliferation [50, 51, 52]. Malignant cells also express BAFF, APRIL, and their receptors,
however, at a significantly lower rate [53, 54, 55], B-cell maturation antigen (BCMA) and CD267
(TACI). Two receptors connect APRIL–BCMA and TACI. Ligands BAFF and/or APRIL lower
the spontaneous and drug-induced apoptosis of CLL cells [53, 54, 55]. In recent years, it has
been proven experimentally that BAFF in cooperation with MYC protein, that plays a role in
cell cycle progression, apoptosis and cellular transformation, causes the development of
lymphocytic proliferation in mice that is similar to CLL [56]. MYC and its target genes are
highly expressed in CLL cells in lymph nodes [4], which is stimulated by BAFF [56] and BCR
activation in vitro [57].
2.5. Monoclonal B cells
The cell traffic between the blood and secondary lymphoid tissues is controlled by tissue-
specific chemokines and their specific receptors on lymphocytes. The chemokine receptors
expressed on neoplastic CLL cells drive migration to proliferation centers (Figure 1; Table 1).
3. Chemokine receptors on monoclonal B cells
3.1. CD184 (CXCR4) expression
The CD184 receptor binds CXCL12 (stromal cell-derived factor-1/SDF-1), a ligand character‐
ized as a pre-B cell growth factor [58]. It is highly expressed on the peripheral blood leukemic
cells surface, facilitates the chemotactic migration through vascular endothelium to bone
marrow stromal cells following the CXCL12 gradient [35, 48, 55, 58, 59]. CD184 surface
expression is regulated by the ligand CXCL12 through receptor endocytosis occurring as a
result of activation [58]. This feature can be used to distinguish tissue leukemic cells expressing
low levels of CD184 from blood CLL cells, which express high levels of CD184 [4, 58]. Prolif‐
erating CLL lymphocytes from bone marrow and lymphoid tissue show significantly lower
levels of CXCR4 and CXCR5, compared to the non-proliferating ones [60, 61]. The BCR signals
also decrease the expression of CD184 [62, 63]. As BCR signals may increase via Zap-70 [64],
monoclonal B lymphocytes expressing Zap-70 have increased chemotaxis and survival as a
response to CXCL12 compared to Zap-70 negative leukemic cells [65], the result of increased
BCR signals. Leukemic cells expressing CD38 also show increased chemotaxis [66] compared
to CXCL12, which can be inhibited by blocking with anti-CD38 monoclonal antibodies [67].
The signals conducted by CD184 induce mobilization of calcium, activation of PI3Ks [58],
p44/42 MAPKs [48], and serine phosphorylation of STAT3 [35]. The signals conducted by
CD184 can be inhibited by selective isomorphic inhibitors - the PI3K inhibitors [68] and the
spleen tyrosine kinase (SYK) inhibitors [62], thus resulting in impaired migration of both the
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normal B cells and the leukemic cells. According to some research teams, the levels of CXCR4
and its ligand CXCL12 correlate to well-established clinical parameters such as the Rai staging
system, while other researchers do not observe correlation with the clinical stage of the disease
or with the type of bone marrow infiltration, instead they report correlation with the lympho‐
cyte count [69, 70]. It should be considered that CD184 is a constitutionally expressed receptor
of B lymphocytes, which could explain the contradictory findings of the different research
teams [71].
3.2. CD181 and CD182 expression
CD181 (CXCR1) and CD182 (CXCR2) have a common ligand - CXCL8. Monoclonal B cells
secrete CXCL8 and express its receptors, which implies both the autocrine and paracrine
stimulation of tumor cell through CXCL8. This stimulation leads to increased expression of
anti-apoptotic protein Bcl-2 and survival of the clone [72].
3.3. CD183 expression
The chemokine receptor CD183 (CXCR3) interacts with three ligands (CXCL9, CXCL10, and
CXCL11) [73]. CD183 is expressed on the surface of malignant cells as a functional receptor
facilitating a directed drive and invasion [70, 73]. Leukemic cells express CXCL9, which
constitutes proof of the autocrine way of a neoplastic growth stimulation, in addition to the
paracrine way. Studies show correlation between the low expression of CD183 in the advanced
stage of the disease (Rai III and Rai IV), non-mutated IGHV status, high CD38 expression, and
the shortened general survival span of the patients. It is suggested that the lower levels of
CD183 could be used as an independent adverse prognostic factor [74]. Nevertheless, the
significance of CXCR3 remains disputable.
Figure 1. Chemokine receptors and chemokines involved in monoclonal B cell activation, migration, and proliferation




CD197 (CCR7) is the main receptor responsible for the traffic of dendritic cells, the B- and T-
lymphocytes through the high endothelial venules and their localization in the T cell zones of
the secondary lymphoid organs. Its ligands - CCL19 and CCL21 are expressed in the T cell
zone of secondary mucosa-associated tissues and high endothelial venules but not in the B cell
zones, sinuses, and peripheral blood. CD197 is expressed mainly by naïve T lymphocytes but
can be detected at certain levels also on B lymphocytes. The role of the receptor for the
development of the secondary lymphoid organs has also been proven [12]. The expression of
CD197 on leukemic B cells is significantly higher in patients with lymphadenopathy, compared
to patients with organomegaly. The CD197-CCL21 binding activates intracellular signaling
pathways, which lead to elevated expression of MMP-9 and infiltration of leukemic cells
through basal membranes [12]. The increased expression of CD197 on Zap-70+ CLL cells
enhances the response of CD197 to ligands [64], and the CD5 phosphorylation additionally
stimulates its surface expression [75]. The binding of both CD197 and CD185 to the respective
ligands elevates the expression of the partially expressed gene 10 (PEG10) in CD23+ CD5+ CLL
cells. The increased synthesis of protein stabilizes caspase-3 and caspase-8 (which normally
are pro-apoptotic proteins), protects them from degradation, thus leading to suppression of
the TNF-α induced apoptosis [76, 77]. A correlation of CD197 with the Rai staging system has
been found, which shows the need of further studies on the possible prognostic significance
of this receptor [71].
RECEPTOR LIGAND CLL EXPRESSION FUNCTION
CD181 (CXCR1)
CD182 (CXCR2) CXCL8 (IL-8) Aberrant or activation expression
Inhibition of apoptosis by up-
regulation of Bcl-2
CD183 (CXCR3) CXCL9, CXCL10,CXCL11






High, low in receptor endocytosis
as a result of interaction with
CXCL12
Contact-dependent inhibition of
apoptosis. Migration and homing
CD185 (CXCR5) CXCL13 High Migration,inhibition of apoptosis
CD197 (CCR7) CCL19,CCL21
Moderate to high, correlates with
lymphadenopathy Inhibition of apoptosis
Table 1. Chemokine receptors and corresponding chemokines
3.5. Chemokines secreted by B cells
Activated monoclonal lymphocytes secrete the CCL3, CCL4 [59], and CCL22 [13] chemokines
that participate in the adaptive immune response and are chemo-attractants for T lymphocytes
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and monocytes (Table 2). CCL3 and CCL4 are normally secreted by B cells after the activation
through BCR and CD40–CD40L interaction [59, 62]. CCL3 secreted from tumor cells induces
T cell traffic to the activated CD38+/Ki-67+ leukemic lymphocytes for the purpose of enabling
intercellular interactions, which enhance proliferation [62]. Similarly to CCL3 and CCL4,
CCL22 participates in the process of attraction of T cells in tissues. It acts as a secondary signal
to T lymphocytes; its secretion from malignant cells starts after attachment of CD40 to CD40L
[13]. The monoclonal population in peripheral blood does not secrete CCL22; secretion is
observed in lymph nodes and bone marrow, probably also as a result of the attachment to
CD40. In classifying CLL patients on the basis of their response to CD40 ligation, it was found
that the patients who did not show a response have less time until disease progression and a
possibility for proliferation of B cells in conditions of lower stromal stimuli [78] (Figure 1).
CHEMOKINE RECEPTOR CLL EXPRESSION SUPPOSED FUNCTIONS
CCL3 CCR1,CCR5 After activation by BCR, higher inZap-70+ CLL-cells, SYK–
dependent
In case of inflammation, activation of
polymorphonuclear leukocytes and B
cells
Supports T cells in T-B cell interactionsCCL4 CCR5
CCL22 CCR4 After CD40 ligation Supports regulatory T cells
Table 2. Chemokine receptors and corresponding chemokines secreted from CLL cell [72]
4. Cell adhesion molecules on monoclonal B cells
Adhesion molecules facilitate the migration of leukemic cells to proliferation centers in bone
marrow and secondary lymphoid tissues [79]; some of them show anti-apoptotic activity and
a relation to drug resistance by binding to their receptors, which are expressed from bone-
marrow stromal cells. The profile of CLL cells in regards to adhesion molecules has been the
subject of studies in recent years since it determines the capacity of leukemic lymphocytes for
response to chemokines and migration to regions, where antigens and additional activation
stimuli influence B lymphocytes (Figure 2).
4.1. CD38 expression
The CD38 receptor performs and modulates a series of intracellular signals initiated by the
cells of microenvironment. The percentage of CD38+ cells in the CLL clone is an indicator of
the current level of cell activation; the cells with a higher expression of CD38 are better receivers
of activation signals and hence the more aggressive portion of the malignant lymphocytes.
Studies on patients with CLL using the incorporation in vivo of deuterium (2H) in the form of
heavy water (2H2O) in a cellular DNA have proved higher proliferation rate of CD38+
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lymphocytes in comparison to CD38− cells [1]. CD38 + B lymphocytes react more effectively in
binding to surface immunoglobulins (sIg), with Zap-70 also participating in this process. The
ligand of CD38–CD31 is expressed on vascular endothelium cells and facilitates cell adhesion.
The aggressiveness of CD38+ lymphocytes is mediated by their ability to migrate and interact
with the cellular microenvironment. CD38 and Zap-70 are functionally related and define the
cells with a higher migration potential [66]. In most of CLL patients, the proportion of CD38+
cells does not exceed a threshold of 30%, which defines the clone as positive. Disease progres‐
sion is more common in the smaller proportion of patients with a CD38 expression defined as
positive [80]. The higher proliferative potential of these lymphocytes suggests novel genomic
disorders and clonal evolution [81, 82, 83, 84], which is supported by the increased incidence
of the observed 11q and 17p deletions [85].
4.2. CD49d expression
The level of CD49d (VLA-4) positive B lymphocytes has been recognized as an independent
prognostic factor in CLL. CD49d is α-integrin subunit (α4), which together with CD29 (β1
subunit) forms the α4β1 integrin binding fibronectin and VCAM-1. Similarly to other integrins,
α4β1 mediates the adhesion of cells to the extracellular matrix, the first step of cell migration.
CD49d and CD38 participate in the formation of a large macromolecular complex that includes
CD49d, CD38, CD44v, and MMP-9 and has been observed in CLL cells without somatic
mutations [86]. The physical and functional binding between CD49d/CD29 and CD38 has been
proven in CLL [87].
In recent years, CD49d adhesion molecule facilitating both the intercellular contact and the
adhesion to extracellular matrix has been established as a new prognostic marker. A multi-
center study on 2,972 patients with CLL validated the prognostic significance of CD49d as an
independent flow cytometric prognostic marker in terms of overall survival and time-to-
treatment start, as defined over a threshold of 30% [88].
4.3. CD44 expression
The CD44 protein family comprises a large group of transmembrane glycoproteins obtained
through alternative splicing and post-translational modification. The considerable degree of
heterogeneity in molecular structure predetermines various essential functions. CD44 medi‐
ates interactions between cells and the extracellular matrix, delivers signals acting as a co-
receptor for tyrosine kinases localized in cell membranes or by binding to intracellular
signaling molecules and activating intracellular signaling pathways. The expression of
different CD44 isoforms depends on the cell type, stage of activation, and differentiation. The
participation of CD44 in the development and progression of hematological neoplasms is
associated with the increase of apoptotic resistance, invasiveness, regulation of bone-marrow
infiltration, and mobilization of leukemic cells in peripheral blood [89]. The surface levels of
CD44v in CLL are associated with advanced clinical stage, resistance to therapy, and decreased
survival [90]. Unlike other cooperating adhesion molecules such as CD11a, CD49d, CD54,
CD58, and CD62L, the expression of CD44 and CD11c correlates with the splenal presentation
of the disease [91]. Soluble CD44 is associated with shortened progression free survival [92],
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while soluble CD44s and CD44v6 are associated with lymphadenopathy, advanced clinical
stage, and resistance to chemotherapy [93]. The results of an in vitro study of the anti-apoptotic
effects of CD44 in CLL cells showed protective action of cultured CLL cells with HK-cells
against spontaneous apoptosis in increased levels of Mcl-1 (a member of the anti-apoptotic
Bcl-2 family). In this study, the blocking of CD44 by monoclonal antibodies leads to a decrease
of Mcl-1 and suppression of the protective effect of HK-cells, demonstrating that the anti-
apoptotic mechanism is CD44-dependent [47]. The formation of macromolecular complexes
from CD44v, CD49d, and MMP-9 on the cells of CLL, but not on normal B lymphocytes, as
well as increased secretion of MMP-9 under the action of CD44 antibodies, reveals the
molecular mechanism of regulation of invasion [94].
4.4. CD54 expression
CD54 is a glycoprotein that is expressed on the surface of vascular endothelium cells, macro‐
phages, and lymphocytes. It binds type CD11a/CD18 and type CD11b/CD18 integrins. In case
of cytokine stimulation by IL-1 and TNF-α, the concentrations of CD54 increase significantly
[95]. Upon activation, cells connect to the endothelium via CD54–CD11a/CD18 and penetrate
tissues [96]. A significant reduction of CD54 expression levels has been demonstrated in CLL
patients compared to a control group of healthy subjects [97]. β1 and β2 integrins of the
malignant B cell, acting simultaneously, mediate the connection of CD54 to bone-marrow
stromal cells and protect them from apoptosis, while normal B lymphocytes cannot be
protected by stromal cells due to the loss of this adhesion connection [36].
Figure 2. Adhesion molecules and their main functions directly relevant to CLL




In the process of lymphocyte homing, B lymphocytes adhere and then enter sinusoidal
endothelium before invasion in efferent lymph nodes, after which they leave the lymph nodes.
CD62L (L-selectin), a member of the selectin family of adhesion molecules, plays an important
role in the traffic and homing of lymphocytes to lymph nodes [98]. CD62L is considered the
main adhesion molecule connecting B cell to sinusoidal endothelial cells through interaction
with mannose receptor [99]; therefore it is believed that CD62L participates in mechanisms
supporting the departure of lymphocytes from lymph nodes. In vitro studies of CLL cells
demonstrated that stimulation through BCR causes a decrease of CD62L, in particular the
expression on cells of patients with adverse prognostic factors and at risk of disease progres‐
sion. The decreased level of surface CD62L is due to disaffiliation from the cell membrane and
leads to an increase of its plasma levels [63]. A similar process is also seen in B cells activated
by formyl peptides and phorbol 12-myristate 13-acetate [100, 101]. Functionally, leukemic
lymphocytes, in which the expression of CD62L and CD184 decreases in a response to BCR
signals, show reduction of migration to CXCL12 and adhesion to endothelial cells of the lymph
node [63]. The adhesion molecule CD62L is the main factor for B cell departure from lymphatic
tissue via connection with lymphatic endothelium [63]. After antigen activation, B lympho‐
cytes lose surface expression of CD62L and do not adhere to the endothelium in lymph nodes
[99, 102]. These cells remain in a close contact with the microenvironment and with the antigen
stimulation, resulting in proliferation and lymph node enlargement. On the contrary, CLL
cells, which do not respond to BCR stimuli, exit lymphoid organs quickly and recirculate like
normal B lymphocytes, due to their ability to recognize a specific antigen [103]. In an in vitro
study of CLL lymphocytes, increased expression of CD62L was associated with prolonged
survival of the malignant cells. Since anti-apoptotic signals from the stromal cells were CD62L-
dependent, the inhibition of CD62L by antibodies decreased the survival of the tumor cells.
The study also showed over-expression of CD62L on malignant B lymphocytes localized in
the proliferation centers of lymph nodes and bone marrow [104]. The immunophenotypic
analysis of CLL cells in the process of culturing has demonstrated a change in the surface
markers participating in intercellular contacts and conducting anti-apoptotic signals. Blockage
of the activation and homing receptor CD62L induces cell death, equivalent to currently used
chemotherapeutics [105].
5. B cell receptor complex
В cell receptor complex (BCRC) is a multimeric complex composed of a surface immunoglo‐
bulin homodimer and a non-covalently bound heterodimer Igα/Igβ (CD79a/CD79b). The
signal pathway of BCRC supports cell proliferation and induces the production of antibodies
in normal B lymphocytes. Binding to a specific antigen activates BCRC, which delivers a signal
to kinases (spleen tyrosine kinase (SYK) and LYN), which phosphorylate and activate Igα/Igβ
[106]. This phosphorylation step triggers a cascade of intracellular signals including activation
of Bruton tyrosine kinase (BTK) and Phosphatidylinositaol 3-kinase (PI3K), which induce the
mobilization and activation of further kinases (protein kinase C-β and mitogen-activated
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protein kinase - ERK) [107]. The activation of this cascade facilitates anti-apoptotic events and
the proliferation of B cells through the enhancement of transcription factors such as the nuclear
factor–κB (NF-κB) [108]. This signal pathway plays an important role in the pathogenesis of
CLL, which has been supported by the following facts:
• Mutation status  of  BCR sequences  is  the  best  prognostic  marker  for  disease  progres‐
sion [109].
• About  20%  of  untreated  patients  express  very  similar,  sometimes  identical,  antigen
receptors.
• Signals of BCRC play a significant role in trafficking, homing, and interactions in microen‐
vironment [110].
There is a 10-fold decrease in the expression of membrane immunoglobulins [111] due to a
critical defect in the formation of the BCR structure [112]. As a result, the stimulation of
monoclonal B cells through BCR is impaired. Low expression of BCRC correlates with reduced
induction of tyrosine kinase activity and affected intracellular mobilization of calcium and
phosphorylation of tyrosine [113]. This low expression is a distinguishing feature of the
disease, since similar expression is not found in other mature B cell lymphoproliferative
diseases. What causes of this phenomenon is still unclear and is addressed in one study [114],
while currently there is a consensus that no genetic defects are present in the components of
BCRC [115]. Except in rare cases, surface IgM and CD79b are expressed on CLL cells in very
low levels, compared to normal B lymphocytes, but the levels of mRNA and intracellular
synthesis of the BCRC components are normal [112]. The correct binding is very important for
proteins that consist of multiple subunits. This process takes place in the endoplasmic
reticulum, where proteins are modified (split of signal peptides, N-glycosylation, formation
of disulfide bridges). In case of failure of the maturation process sequence, various system
control mechanisms are activated. They prevent the production of non-functional proteins. A
study showed that a complete IgM is not transported to the membrane of the CLL cell [116,
117]. Monoclonal B lymphocytes have a phenotype, which is similar to naïve B cells from the
mantle zone, they express CD5 and IgM/IgD and during a normal maturation process they
should have expressed non-mutated immunoglobulin genes [118]. However, CLL cells in 50–
70% of patients have somatic mutations of the IGHV genes [119], therefore they should have
completed the stage of maturation in the lymph follicle. The nature of the leukemic clone is
still not established [120, 121], and the absence or presence of somatic mutations is associated
with the functioning of single IGHV genes [122].
6. Costimulatory receptors on monoclonal B cells
Cells proliferate in lymph nodes and bone marrow, where under the influence of microenvir‐
onment stimuli, they interact with stromal cells and T lymphocytes, resulting in apoptosis
impairment and an increase of proliferation. The gene expression profile of CLL cells corre‐
sponds to that of activated B lymphocytes [4].
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Figure 3. In case of binding of an antigen to the BCR, intracellular signals activate and increase the expression of CD40;
the binding to the ligand leads to activation and increased expression of CD86. This in turn leads to activation and de
novo expression of CD80. Both regulatory molecules have common ligands CD28 and CD152; these interactions modu‐
late the proliferation of B and T cells
6.1. CD40 expression
CD40 is a molecule belonging to the tumor necrosis factor receptors (TNFR) family. It is
expressed during B cell development and plays a major role in cell survival and differentiation
[123, 124]. Its physiological ligand CD40L (CD154) is also a member of the TNFR family [125].
Interactions between CD40/CD40L stimulate the proliferation and differentiation of B cells,
dendritic cells, and monocytes and enhance expression of costimulatory molecules and the
antigenic presentation [126, 127]. After antigen recognition, the T cell receptor (TCR) induces
increased CD154 expression on CD4+ T cells, enhances signals through CD40, and increases
the expression of CD80/CD86 on antigen-presenting cells (Figure 3). This system enhances
activation of T cells, their differentiation, and modulates humoral immune response [128]. The
congenital deficit of CD154 in X-linked Hyper-IgM Syndrome leads to frequent bacterial
infections due to impaired switching of immunoglobulin classes [129] similar to the immune
disorders in CLL patients. Leukemic B lymphocytes express variably functional surface CD154,
while CD4+ T cells in CLL patients do not express surface CD154 after CD3 ligation [130,
131]. Binding of CD40 induces expression of CD95, a receptor for apoptotic signals, but
paradoxically it conducts a strong NF-κB mediated signal for the survival of leukemic cells in
vitro [132]. CD40 activation of malignant cells reduces Fludarabine-induced apoptosis in vitro
[133]. In patients with CLL, CD40 activation of B lymphocytes increases the expression of B7
molecules and these cells present alloantigens significantly better than non-stimulated CLL-
cells (Figure 3) [24]. Surface expression of costimulatory molecules increases as the process is
accompanied by an impaired T cell response to alloantigens and tumor antigens in many other
B cell lymphoproliferative diseases [134, 135, 136]. In a study of antigen-presenting capacity
of CD40-activated CLL lymphocytes and dendritic cells stimulated by apoptotic bodies of CLL
cells, both kinds of antigen-presenting types generated specific T cells, proliferating in
response to non-stimulated CLL lymphocytes. T cells isolated from patients with CLL
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recognize and produce allogenic stimulated and non-stimulated CLL lymphocytes, which
shows that the cytotoxic T cells of the patients are functionally intact [137]. CLL lymphocytes
activated through CD40 in the presence of IL-4 and INF-γ increase the expression of CD80 and
Major histocompatibility complex-II (MHC-II) molecules. Antigen presentation of alloantigen
from leukemic cells is comparable to that of normal CD40-activated B cells, as it increases in
the presence of IL-4 and INF-γ [138].
6.2. CD80 and CD86 expression
CD80 and CD86 receptors belong to the B7 family, which is one of the most important
secondary signaling mechanisms for maintaining the balance between adequate immune
response, immunosuppression, and autoimmunity [139].
The expression of CD80 and CD86 is restricted to antigen-presenting cells, as both molecules
play different roles in immune modulation due to different interactions with their ligands
CD28 and CD152, respectively. The interaction of CD80 with CD152 has a higher affinity than
the interaction of CD86 with CD152, while CD28 connects with CD86 more effectively than
with CD80 [140]. Low expression of CD86 is registered on non-activated B cells, dendritic cells,
and macrophages, in case of activation the levels of CD86 increase and CD80 is expressed de
novo [141, 142]. These interactions form a costimulatory–co-inhibitory system that regulates
immune responses (Figure 3). Mice with a CD80 and CD86 deficit are characterized with
disorders in both the humoral and cell immune response [143]. Furthermore, in case of CD28
deficit, the receptor immune response to foreign antigens, infectious pathogens, and trans‐
plants is ineffective [144]. The interaction of CD80 and CD86 with its receptor CD28 generates
costimulatory signals leading to a productive activation, expansion, differentiation, survival
of the B- and T-cells and an effective antibody-mediated and cell immune response. This
immune response is balanced by signals received through interactions with CD152. Mice with
CD152 deficit develop an autoimmune phenotype and die rapidly due to multi-organ
destruction [145]. The lack of signals from CD80 and CD86 precludes the development of
autoimmune deficit in models of triple deficit of CD80, CD86, and CD152 [146]. The role of B7
in antitumor immunity is confirmed through a model system, where cytotoxic T lymphocytes
remove mouse tumors, in which transfection of CD80 and CD86 was performed. Unlike solid
tumors, both molecules are expressed in a number of hematologic diseases [147, 148]. For
instance, cells from a follicular lymphoma increase their expression of CD80 and CD86 as well
as other costimulatory and adhesion molecules after in vitro activation [149]. Malignant Reed
Sternberg cells of classical Hodgkin’s lymphoma also express high levels of CD80 and CD86
[150]. Expression in multiple myeloma is variable and correlates with prognosis [151]. In CLL,
the expression levels are low in non-stimulated malignant lymphocytes and increase after
stimulation [148, 152].
6.3. CD267 (TACI) expression
The CD267 receptor binds to two ligands - BAFF and APRIL, thus inducing activation,
proliferation, and survival of B cells [52, 153, 154, 155]. CD267 is expressed on subsets of B
lymphocytes and activated T cells [156] and the expression varies in different B cell subpopu‐
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lations, the strongest being on marginal-zone B cells and memory CD27+ В lymphocytes [157,
158, 159], and increases after stimulation [160, 161]. In human B cells, BAFF and APRIL induce
IgG and IgA immunoglobulin classes switch in the presence of IL-10 or TGF-β [162]. After the
discovery of the mutations in TNFRSF13b, the regulatory role of expression of CD267 in final
B cell differentiation and binding to Common variable immunodeficiency (CVID) in humans
was established [163, 164]. The binding of BAFF to CD267 stimulates NF-κB activation in B
lymphoma cells in vitro, while soluble forms of CD267 inhibit this induction as well as the
production of IgM by В lymphocytes [165]. CD267 (TACI) was initially defined as a receptor
interacting with Calcium modulating ligand (CAML) meaning that it conducts signals through
both NF-κB and NFAT/AP-1. The binding of BAFF and APRIL to CD267 can also conduct
negative regulatory signals for B cell maturation and activation. In a study on the expression
of CD267 in CLL, a significant decrease of the levels compared to healthy control indicators
was found [166], which raises the question of the significance of CD267 in the pathogenesis of
CLL. The observed lymphocytic proliferation and development of autoimmune diseases in
mice with CD267 deficit suggests that this receptor could conduct pro-apoptotic signals in
activated B cells [167, 168]. In humans, the higher is the expression of CD267 on monoclonal
B lymphocytes the higher is the percentage of apoptotic leukemic cells [166], therefore it was
presumed that the decreased receptor expression reduces the negative regulatory signal to B
cells. The authors also found inverse correlation between CD267 and Bcl-2 expression of the
leukemic cells and a positive correlation between TACI and the expression of prostate
apoptosis response-4 (PAR-4), which is a unique pro-apoptotic protein, selectively inducing
apoptosis in tumor cells [169]. Based on the observation of increased numbers of circulating
and splenal B lymphocytes in TACI–/– deficit mice [167, 170], it can be speculated that CD267
is an inhibitor of B cell proliferation [167]. Similarly, a study of 62 untreated patients with CLL
showed inverse correlation between the amount of CD5+ B cells, leukocyte count, and the
expression of CD267. The study also showed significantly lower expression of the receptor in
Rai stages III and IV patients, as well as in Zap-70+ and CD38+ positive patients, compared to
Zap-70 and CD38– negative [166]. Further studies on the expression of CD267 and the clinical
course of the disease are needed to establish the precise role of this receptor in the progression
of CLL.
7. Conclusion
The phenotypic profile of malignant lymphocytes is of pathological and biological significance.
It reflects the relationship between B cells, the tumor microenvironment, and the importance
of intercellular interactions. Variations in the expression profile of CLL patients reflect different
mutations and impaired regulatory mechanisms. The existence of a complex network of
antiapoptotic and prosurvival molecules, including cell adhesion, proinflammatory, angio‐
genic, and proto-oncogenic molecules, is responsible for supporting the infiltrating malignant
cells and for the maintenance of the neoplastic tissue in CLL. Many prosurvival signaling
pathways potentially sustaining CLL cell maintenance interact with one another. Thus, it
appears that developing new classes of drugs affecting simultaneously various signaling
pathways, and therefore abrogating signaling redundancy-associated chemoresistance to
classical drugs, is feasible.
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